{
  "pmcid": "12209804",
  "sha256": "601073449f5c49280cf60e12652ec0e091b925cb86f0fb8ca4f72f9d345d6cfc",
  "timestamp_utc": "2025-11-09T23:30:20.529704+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 11.578328173374615,
    "reading_ease": 35.95616099071208,
    "word_count": 255
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial on Acute Kidney Disease Post-Acute Kidney Injury"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "Participants were randomised to receive either structured follow-up care (intervention) or standard care (control)."
      },
      "Participants": {
        "score": 2,
        "evidence": "This randomised controlled trial was conducted in a hospital setting. Adult patients with AKI were eligible."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Participants were randomised to receive either structured follow-up care (intervention) or standard care (control)."
      },
      "Objective": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the progression to CKD within 12 months."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was computer-generated, and allocation was concealed using sealed envelopes."
      },
      "Blinding": {
        "score": 1,
        "evidence": "Outcome assessors were blinded to group allocation."
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "A total of 200 participants were randomised: 100 to the intervention group and 100 to the control group, between January 2020 and June 2021."
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "Analysis was conducted on 98 participants in the intervention group and 97 in the control group using an intention-to-treat approach."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "The intervention group demonstrated a reduced progression to CKD (hazard ratio = 0.75, 95% CI 0.60 to 0.90; p = 0.01)."
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events occurred in 3% of the intervention group and 1% of the control group, with mild gastrointestinal side-effects reported."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: NCT12345678"
      },
      "Funding": {
        "score": 1,
        "evidence": "This trial was funded by the National Institutes of Health."
      }
    },
    "total_score": 21,
    "max_score": 25
  }
}